Biotech entity
acquisition is the sole category represented across all 1 tracked stories. PicS N.V. is most often covered alongside Avis Budget Group, which appears in 1 of these 1 story. Each carries 6 original sources on average. We currently track 1 Biotech story that mention PicS N.V., all published on June 15, 2026.
Last mentioned: Jun 15, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
acquisition is the sole category represented across all 1 tracked stories. PicS N.V. is most often covered alongside Avis Budget Group, which appears in 1 of these 1 story. Each carries 6 original sources on average. We currently track 1 Biotech story that mention PicS N.V., all published on June 15, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering PicS N.V.. Shared-story counts are live from our verified record — not editorial picks.
A $31.3 million impairment on the Fabric Genomics deal has drawn a securities lawsuit against GeneDx. For biotech investors, the case highlights the perils of overvalued AI acquisitions in genomics, as GeneDx trimmed its revenue forecast by up to $80 million.
PicS N.V. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
